Mirikizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), DMC (Denmark) and HIRA (South Korea), among others, recommended or restricted mirikizumab, while NYE METODER (Norway) did not recommend it.
The record spans 2.8 years, opening at PBAC (Australia) in 2023 and running to 20 May 2026.
AOTMIT (Poland) changed its position: recommended on 6 Aug 2024, restricted by 20 May 2026.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 22 of 24 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for mirikizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 24 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess mirikizumab, in 2023; DMC (Denmark) did not open a file until 3 Sep 2025 — a moderate spread of 2.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 10 of 22 dated records fall in 2025 alone.
10 of the 12 agencies here assessed mirikizumab more than once, CIPM (Spain) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
mirikizumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for mirikizumab reads 13 recommended, 3 restricted, 3 not recommended and 2 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 19 Nov 2025 | Indicaciones terapéuticas autorizadas: Colitis ulcerosa Omvoh está indicado para el tratamiento de la colitis ulcerosa a… | financed by the SNS · art. 92 a, c | source |
| NYE METODER (Norway) | 21 Sep 2025 | Til voksne med moderat til alvorlig aktiv Crohns sykdom som har hatt utilstrekkelig respons på, tapt respons på, eller e… | not introduced | source |
| G-BA (Germany) | 4 Sep 2025 | Omvoh — benefit assessment §35a | added benefit: not proven | source |
| DMC (Denmark) | 3 Sep 2025 | Behandling af voksne patienter med moderat til svær aktiv Crohns sygdom, som har haft utilstrækkelig respons, mistet res… | Direkte indplacering | source |
| SMC (Scotland) | 11 Aug 2025 | For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to e… | accepted | source |
19 further decisions for mirikizumab, across 12 agencies, are not shown here. They include the most recent record on file, 20 May 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 17 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 24 decisions for mirikizumab from 12 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.